Bayer, Millennium Expand Deal to Include More Diseases | GenomeWeb

NEW YORK, Sept. 19 – Bayer and Millennium Pharmaceuticals said Wednesday they had extended their alliance to look for new drug targets to battle thrombosis, urinary incontinence, and benign prostatic hypertrophy. 

The companies, which began working together in 1998 and have until now focused on cardiovascular diseased, cancer, pain, hematology, and viral infections, said they have so far identified more than 140 potential drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.